THE AMERICAN SOCIETY FOR CELL BIOLOGY (ASCB) ANNUAL MEETING, SAN FRANCISCO, Dec. 13 /PRNewswire-FirstCall/ -- At the American Society for Cell Biology (ASCB) Annual Meeting today, the BioSciences Group of Fujitsu Computer Systems announced a new evaluation project with Whitehead Institute for Biomedical Research, focusing on high-throughput cell-based research.
As part of the project, Fujitsu will provide Whitehead with the CELLINJECTOR automated microinjection system to help develop more efficient workflows for researchers currently working on cell-based assays.
Whitehead researchers will utilize CELLINJECTOR for a variety of research projects, including peptide expression and trafficking in stem cells, assessment of gene expression controls, and the study of cell-signaling cascades, among others.
According to Paul Matsudaira, director of Whitehead Institute-MIT BioImaging Center, "We are looking forward to promising results based on new techniques leveraging automated microinjection technologies. Our researchers envision broad utility of this kind of technology in developing efficient workflows for high-throughput cell-based research."
Dr. Michael J. McManus, vice president of Business Development for the BioSciences Group of Fujitsu Computer Systems, said, "The precision and automation of CELLINJECTOR vastly improves the efficiency and throughput of cell injections, easily performing thousands of successful injections per day compared to hundreds done manually. We are confident that high-throughput injection technologies such as CELLINJECTOR will help advance development of effective microinjection-based techniques across a wide spectrum of research areas, especially for cell types that are notoriously difficult to transfect."
The CELLINJECTOR system is a high-throughput, efficient, automated method for directly injecting a large number of cells. CELLINJECTOR is computer- controlled, so operators do not need extensive injection training to perform efficient cellular injections. The development of CELLINJECTOR was partially supported by a grant from the New Energy and Industrial Technology Development Organization (NEDO) of Japan.
About The BioSciences Group of Fujitsu Computer Systems
The BioSciences Group of Fujitsu Computer Systems Corporation is an established leader in creating innovative and reliable solutions for experimental scientists. BioSciences Group solutions enable researchers to make in silico predictions about leads, targets, and interactions, and to validate these hypotheses experimentally. BioSciences Group offerings include the CELLINJECTOR system for high-throughput, automated cellular injection, the isS(TM) (in silico Screening) platform for large-scale docking and free energy of binding simulations, and the CAChe(TM) suite of life sciences predictive modeling and automated docking tools, for drug discovery lead-generation. For more information, please see: us.fujitsu.com/biosciences.
About Fujitsu Computer Systems
Headquartered in Sunnyvale, Calif., Fujitsu Computer Systems is a wholly owned subsidiary of Fujitsu Limited committed to the design, development and delivery of advanced computer systems and managed services for the business enterprise. The company offers a complete line of high- performance mobile computers, scalable and reliable servers, storage, and middleware as well as managed and professional services. Fujitsu Computer Systems emphasizes leading-edge technology, exceptional product quality and user comfort and productivity, as well as outstanding customer service. More information on Fujitsu Computer Systems is available at: us.fujitsu.com/computers.
Fujitsu is a leading provider of customer-focused IT and communications solutions for the global marketplace. Pace-setting device technologies, highly reliable computing and communications products, and a worldwide corps of systems and services experts uniquely position Fujitsu to deliver comprehensive solutions that open up infinite possibilities for its customers' success. Headquartered in Tokyo, Fujitsu Limited reported consolidated revenues of 4.7 trillion yen (US$44.5 billion) for the fiscal year ended March 31, 2005. For more information, please see: www.fujitsu.com.
About Whitehead Institute
Whitehead Institute for Biomedical Research is a nonprofit, independent research and educational institution. Wholly independent in its governance, finances and research programs, Whitehead shares a close affiliation with the Massachusetts Institute of Technology through its faculty, who hold joint MIT appointments.
Fujitsu, the Fujitsu logo and CELLINJECTOR are trademarks or registered trademarks of Fujitsu Limited in the United States and other countries. All other trademarks and product names are the property of their respective owners.
The statements provided herein are for informational purposes only and may be amended or altered by Fujitsu Computer Systems Corporation without notice or liability. Product description data represents Fujitsu design objectives and is provided for comparative purposes; actual results may vary based on a variety of factors. Specifications are subject to change without notice.
BioSciences Group of Fujitsu Computer Systems Corporation